Anzeige
Mehr »
Login
Dienstag, 28.05.2024 Börsentäglich über 12.000 News von 690 internationalen Medien
Massiver Kaufalarm bei (noch) unbekanntem Kupfer-Star!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 936386 | ISIN: US8006771062 | Ticker-Symbol: GBY
Tradegate
28.05.24
18:02 Uhr
0,610 Euro
+0,029
+5,05 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SANGAMO THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SANGAMO THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,5910,61118:25
0,5910,61118:05

Aktuelle News zur SANGAMO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.05.Sangamo Therapeutics GAAP EPS of -$0.27 misses by $0.05, revenue of $0.48M misses by $5.88M21
09.05.SANGAMO THERAPEUTICS, INC - 8-K, Current Report4
09.05.Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results155RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results. "Sangamo...
► Artikel lesen
09.05.Sangamo Therapeutics, Inc.: Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing266Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale...
► Artikel lesen
25.03.SANGAMO THERAPEUTICS, INC - 8-K, Current Report36
22.03.Sangamo Prices Direct Offering39
22.03.Sangamo Therapeutics looks to raise $24M in a direct offering; shares fall25
22.03.Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering574Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase...
► Artikel lesen
19.03.H.C. Wainwright lifts Sangamo stock PT to $5 on SIFTER platform optimism27
13.03.Sangamo Therapeutics Inc reports results for the quarter ended in December - Earnings Summary13
13.03.Sangamo Therapeutics GAAP EPS of -$0.34 misses by $0.08, revenue of $2.04M misses by $6.07M8
13.03.Sangamo reports breakthrough in brain delivery technology15
13.03.Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results149RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial...
► Artikel lesen
13.03.SANGAMO THERAPEUTICS, INC - 8-K, Current Report4
13.03.SANGAMO THERAPEUTICS, INC - 10-K, Annual Report3
12.02.Sangamo stock soars 37% on updates for Fabry disease therapy139
12.02.Sangamo Therapeutics Reports U.S. And European Regulatory Support For ST-92057
12.02.Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease814U.S. Food and Drug Administration (FDA) advises that a single study with up to 25 patients, in combination with confirmatory evidence, may be acceptable pathway to Biologics License Application (BLA)...
► Artikel lesen
06.02.SANGAMO THERAPEUTICS, INC - 8-K, Current Report14
19.01.SANGAMO THERAPEUTICS, INC - 8-K, Current Report33
Seite:  Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,9